ArticleJournal of thoracic disease2022
Clinical significance of mean corpuscular volume as a prognostic indicator of radiotherapy for locally advanced lung cancer: a retrospective cohort study.
Article in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prognostic Significance of the CALM Index in Surgically Resected Non-Small Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Mean Corpuscular Volume as a Prognostic Marker in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection: A Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- The Prognostic Immune and Nutritional Index as a Predictor of Survival in Resected Non-Small Cell Lung Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Prognostic Significance of Modified Shine and Lal Index in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection.Biomedicines · 2025Article
- The mean reticulocyte volume is a valuable index in early diagnosis of cancer-related anemia.PeerJ · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the prognosis of solid tumors is related to the mean corpuscular volume (MCV), which can roughly predict the prognosis of patients, its correlation with locally advanced lung cancer is still unclear. We evaluated the relationship between serum MCV levels and prognosis in patients before radiotherapy. Methods: We retrospectively collected the age, sex, smoking history, TNM stage, ECOG score, hematocrit (HCT), MCV, mean corpuscular hemoglobin (MCH), and red blood cell distribution width-standard deviation (RDW-SD) of patients with locally advanced lung cancer who received chest radiotherapy from 2013 to 2017, and analyzed the relationship between this information and the overall survival (OS). Results: Among all patients, 89 were male (79.5%), 23 were female (20.5%), 46 (41.1%) were older than 65 years, and 66 (58.9%) were younger than 65 years. Seventy-four patients had MCV <93.65 fL, 38 patients had MCV ≥93.65 fL, and the median follow-up period was 24 months. The patients with high T stage, high N stage, and high MCV had lower OS (P<0.05). In the Cox regression analysis, MCV [odds ratio (OR) =0.534, 95% confidence interval (CI): 0.349-0.818, P=0.01], T stage (OR =0.654, 95% CI: 0.440-0.972, P=0.04) and N stage (OR =0.545, 95% CI: 0.371-0.801, P=0.01) were predictors of prognosis. Conclusions: In the clinical treatment of patients with locally advanced lung cancer, MCV can be used to roughly predict their survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.